View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharmaxis 過去の業績過去 基準チェック /36Pharmaxisは、平均年間11.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.4% 15.2%収益成長率で 減少しています。 Pharmaxisの自己資本利益率は12.9%であり、純利益率は12.3%です。主要情報11.51%収益成長率7.44%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率-15.24%株主資本利益率12.87%ネット・マージン12.30%次回の業績アップデート28 Jul 2023最近の業績更新お知らせ • Apr 24Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024お知らせ • Nov 30+ 2 more updatesPharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023Pharmaxis Ltd announced that they will report Q3, 2023 results on Apr 28, 2023すべての更新を表示Recent updatesお知らせ • Oct 01Syntara Limited, Annual General Meeting, Nov 20, 2025Syntara Limited, Annual General Meeting, Nov 20, 2025.お知らせ • Sep 30Syntara Limited, Annual General Meeting, Nov 28, 2024Syntara Limited, Annual General Meeting, Nov 28, 2024.お知らせ • Aug 16Syntara Limited Announces CFO ChangesSyntara Limited announced the appointment of Tim Luscombe as Chief Financial Officer (CFO) for Syntara, effective 31 August 2024. Tim replaces Mr. David McGarvey, who is retiring after more than 20 years as the CFO of Syntara, and before that Pharmaxis. David will continue in his role as Company Secretary to the Board. Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies. Tim holds a Bachelor of Commerce from the University of Melbourne, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. In addition to his role as Company Secretary Mr. McGarvey will give special attention to concluding financial and legal arrangements associated with the sale of the mannitol business unit.お知らせ • Apr 24Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024お知らせ • Feb 06Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,392,130 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,153,325 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct Listingお知らせ • Dec 20Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,400,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,200,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct Listingお知らせ • Oct 20Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis on October 19, 2023.お知らせ • Oct 05Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023.お知らせ • Sep 13Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023, at 11:01 AUS Eastern Standard Time.お知らせ • Jan 17Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive DirectorPharmaxis Ltd. announced the appointment of healthcare investment professional Hashan De Silva to the Board as a nonexecutive director. Mr. De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr. De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals. Mr. De Silva was educated at the University of New South Wales (Bachelor's Degree in Medicine and Master's Degree in Finance) and is a Chartered Financial Analyst. Until December 2022 Mr. De Silva was Head of Healthcare Research at Karst Peak Capital Limited, a Hong Kong and Australian based specialist healthcare fund and is a nonexecutive director of Melbourne and Philadelphia based CurveBeam AI. Mr. De Silva is based in Sydney Australia and commences his role as nonexecutive director on 16 January 2023.お知らせ • Dec 22Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 PatientsPharmaxis announced that the clinical trial of its topical anti scarring drug PXS6302 has completed recruitment with the last of the 42 patients dosed earlier this week. The study is being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM, Director of the Western Australia Burns Service. The trial, known as SOLARIA2, is in 50 adult patients treated for scars of greater than one year in age and over 10cm2 in size for a period of 3 months. The first 8 patients treated were on active drug whereas the following 42 were randomised 1:1 to active or placebo. Preliminary results, released in September from the open label phase with 8 patients treated for up to 3 months on active drug, showed a high level of inhibition of enzymes and changes in biomarkers that are implicated in scarring with Professor Fiona Wood commenting. Final results are scheduled for second quarter 2023 when the company hopes to confirm an acceptable safety profile, improvements in scar appearance and function for patients on active drug relative to those treated with placebo, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level. PXS6302 was discovered by the company research team at the company's Frenchs Forest laboratories. The project was supported by a National Health and Medical Research Council (NHMRC) development grant which funded extensive preclinical work executed in collaboration with UWA. The ongoing clinical trial in patients with established scars and the planned follow up study will both be conducted at the Fiona Stanley Hospital in Perth with financial support from the company.お知らせ • Dec 14Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive DirectorPharmaxis Ltd. announced the appointment of experienced senior global pharma executive Dr Simon Green to the Board as an independent nonexecutive director. Dr Green has 30 years of experience in the biotechnology industry focused on the discovery, development and commercialization of life saving medicines. He worked in the USA at leading biotechnology companies Genentech Inc. and Chiron Corporation prior to joining CSL in 1998. Dr Green was actively involved in CSL's global expansion over a 17 year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Dr Green's breadth of skills covers R&D drug development, corporate due diligence, mergers and acquisitions, strategic planning, portfolio management, financial management, intellectual property management, business development, contract management and organizational design. Dr Green was educated at Monash University (Bachelor's Degree with Honours) and the University of Melbourne (Doctor of Philosophy, Biochemistry and Immunology). He is a graduate of the Australian Institute of Company Directors Company Directors Course. Dr Green is a nonexecutive director of Clover Corporation Limited and is the founder and CEO of Immunosis Pty Ltd, a startup diagnostics Company. He is also a Venture Partner and investment advisor at BioScience Managers, a healthcare investment firm and serves on the scientific advisory board for Imunexus Pty Ltd. Dr Green is based in Melbourne Australia and will take up his role as nonexecutive director on 16 December 2022.お知らせ • Nov 30+ 2 more updatesPharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023Pharmaxis Ltd announced that they will report Q3, 2023 results on Apr 28, 2023お知らせ • Oct 25Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022, at 10:00 AUS Eastern Standard Time.お知らせ • Oct 19Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis TrialPharmaxis Ltd. has concluded an interim analysis of data from 6 patients who have completed 6 months' treatment with PXS-5505 in its open label phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis. The phase 2 trial known as MF-101 was cleared by the FDA under the Investigational New Drug (IND) scheme and aims to demonstrate that PXS-5505, the lead asset in Pharmaxis' drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs. These patients have very limited treatment options and a life expectancy of approximately 1 year. A total of 15 patients have been enrolled in the cohort expansion phase of the study with 6 patients having completed 24 weeks of treatment. Four patients have dropped out of the study due to a lack of clinical response. PXS-5505 has been well tolerated with no serious treatment related adverse events reported. 2/6 patients had clinically important improvement in symptoms. 5/6 patients had either stable or improved bone marrow fibrosis scores of 1 grade. 5/6 have stable or improved platelet and/or haemoglobin scores. No reductions were seen in spleen volume. A total of 18 clinical trial sites are now actively recruiting in Australia, South Korea, Taiwan and the US with two more sites due to open in Q4. Recruitment is expected to complete by the end of 2022 with top line results available in Third Quarter 2023. While Pharmaxis' primary focus is the development of PXS-5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancer where it aims to break down the fibrotic tissue in tumours and enhance the chemotherapy treatment. An investigator led phase 1c study in newly diagnosed hepatocellular cancer patients, where PXS-5505 will be used in addition to immunotherapy standard of care, is due to commence recruitment at Rochester University New York in Fourth Quarter 2022.お知らせ • Sep 26Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring StudyClinical stage drug developer Pharmaxis announced interim data from the clinical trial of its topical anti scarring drug PXS6302 being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM, Director of the Western Australia Burns Service. The trial, known as SOLARIA2, is in 50 adult patients treated daily for scars of greater than one year in age and over 10cm2 in size for a period of 3 months. The first 8 patients treated were on active drug whereas the following 42 are being randomised 1:1 to active or placebo. Preliminary results from open label phase with 8 patients treated for up to 3 months on active drug are: Skin punch biopsies taken 24 hrs after application at the end of the treatment period, show skin penetration and high inhibition of the lysyl oxidase enzymes that, based on preclinical models, are fundamental to the scarring process. Reduction in the scarring biomarkers hydroxyproline and LOX was observed in the biopsies and based on preclinical models of the scarring process, suggests a normalisation of physiological processes and a disease modifying effect. Four patients withdrew from the study after experiencing redness and itching at the site of application that resolved on treatment cessation. In the second placebo controlled phase of the study, 24 out of the planned 42 patients have been recruited. In response to the adverse skin reaction seen with some patients in the unblinded active phase, the treatment regimen has been reduced from once daily to three times a week application to reduce drug exposure whilst maintaining a high level of enzyme inhibition. Final results are expected in H1 2023 when Pharmaxis hopes to confirm an acceptable safety profile, improvements in scar appearance and function for patients on active drug relative to those treated with placebo, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level. In a separate development, UWA researchers last week published the preclinical studies performed in collaboration with Pharmaxis on topical treatment of skin scars with a pan LOX inhibitor that underpinned SOLARIA2. The preclinical studies, published in Nature Communications, clearly demonstrated that lysyl oxidase enzymes play a critical role in scar formation and maintenance by stabilising collagen, and driving scar stiffness and appearance. The inhibition of these enzymes by Pharmaxis' topically applied drug was shown to normalise collagen assembly and reduce fibrosis in different skin scar models (scleroderma, burn and hypertrophic scars). The preclinical data included in the publication were favourably reviewed by the FDA in preIND discussions with Pharmaxis where feedback was also useful in understanding potential endpoints of value in any regulatory process and the limitations of existing patient reported outcome measures. PXS6302 was discovered by the Pharmaxis research team at the company's Frenchs Forest laboratories. The project was supported by a National Health and Medical Research Council (NHMRC) development grant which funded extensive preclinical work executed in collaboration with UWA. The ongoing clinical trial in patients with established scars and the planned follow up study will both be conducted at the Fiona Stanley Hospital in Perth with financial support from Pharmaxis.収支内訳Pharmaxis の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PMXS.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 2216215030 Sep 2218215030 Jun 2216-215031 Mar 2214-1615031 Dec 2119-1215030 Sep 2128-116030 Jun 2124-316031 Mar 2127516631 Dec 2022-416-230 Sep 2012-1316630 Jun 2013-1416031 Mar 2013-2117731 Dec 1913-1817730 Sep 1913-1816730 Jun 1912-2017931 Mar 197-2717931 Dec 1822-1217930 Sep 1821-22171030 Jun 18496161031 Mar 185110161331 Dec 1737-1161330 Sep 17367151330 Jun 179-18151531 Mar 178-16151331 Dec 167-16151430 Sep 168-14151630 Jun 1610-16151531 Mar 164716161731 Dec 154814171530 Sep 154921191530 Jun 154718211331 Mar 155-34132231 Dec 148-38251230 Sep 145-51161730 Jun 149-5228731 Mar 145-44181631 Dec 136-43251330 Sep 134-43202030 Jun 133-44202431 Mar 133-41192931 Dec 122-40192430 Sep 122-39183030 Jun 121-391624質の高い収益: PMXS.Fは 高品質の収益 を持っています。利益率の向上: PMXS.F過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PMXS.F過去 5 年間で収益を上げており、収益は年間11.5%増加しています。成長の加速: PMXS.Fは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: PMXS.F昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: PMXS.Fの 自己資本利益率 ( 12.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/06/06 14:31終値2023/03/09 00:00収益2022/12/31年間収益2022/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Syntara Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Anubhav SaxenaBell PotterThomas WakimBell PotterMadeleine WilliamsCanaccord Genuity6 その他のアナリストを表示
お知らせ • Apr 24Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024
お知らせ • Nov 30+ 2 more updatesPharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023Pharmaxis Ltd announced that they will report Q3, 2023 results on Apr 28, 2023
お知らせ • Oct 01Syntara Limited, Annual General Meeting, Nov 20, 2025Syntara Limited, Annual General Meeting, Nov 20, 2025.
お知らせ • Sep 30Syntara Limited, Annual General Meeting, Nov 28, 2024Syntara Limited, Annual General Meeting, Nov 28, 2024.
お知らせ • Aug 16Syntara Limited Announces CFO ChangesSyntara Limited announced the appointment of Tim Luscombe as Chief Financial Officer (CFO) for Syntara, effective 31 August 2024. Tim replaces Mr. David McGarvey, who is retiring after more than 20 years as the CFO of Syntara, and before that Pharmaxis. David will continue in his role as Company Secretary to the Board. Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies. Tim holds a Bachelor of Commerce from the University of Melbourne, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. In addition to his role as Company Secretary Mr. McGarvey will give special attention to concluding financial and legal arrangements associated with the sale of the mannitol business unit.
お知らせ • Apr 24Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024
お知らせ • Feb 06Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,392,130 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,153,325 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 20Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,400,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,200,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 20Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis on October 19, 2023.
お知らせ • Oct 05Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023.
お知らせ • Sep 13Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023, at 11:01 AUS Eastern Standard Time.
お知らせ • Jan 17Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive DirectorPharmaxis Ltd. announced the appointment of healthcare investment professional Hashan De Silva to the Board as a nonexecutive director. Mr. De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr. De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals. Mr. De Silva was educated at the University of New South Wales (Bachelor's Degree in Medicine and Master's Degree in Finance) and is a Chartered Financial Analyst. Until December 2022 Mr. De Silva was Head of Healthcare Research at Karst Peak Capital Limited, a Hong Kong and Australian based specialist healthcare fund and is a nonexecutive director of Melbourne and Philadelphia based CurveBeam AI. Mr. De Silva is based in Sydney Australia and commences his role as nonexecutive director on 16 January 2023.
お知らせ • Dec 22Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 PatientsPharmaxis announced that the clinical trial of its topical anti scarring drug PXS6302 has completed recruitment with the last of the 42 patients dosed earlier this week. The study is being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM, Director of the Western Australia Burns Service. The trial, known as SOLARIA2, is in 50 adult patients treated for scars of greater than one year in age and over 10cm2 in size for a period of 3 months. The first 8 patients treated were on active drug whereas the following 42 were randomised 1:1 to active or placebo. Preliminary results, released in September from the open label phase with 8 patients treated for up to 3 months on active drug, showed a high level of inhibition of enzymes and changes in biomarkers that are implicated in scarring with Professor Fiona Wood commenting. Final results are scheduled for second quarter 2023 when the company hopes to confirm an acceptable safety profile, improvements in scar appearance and function for patients on active drug relative to those treated with placebo, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level. PXS6302 was discovered by the company research team at the company's Frenchs Forest laboratories. The project was supported by a National Health and Medical Research Council (NHMRC) development grant which funded extensive preclinical work executed in collaboration with UWA. The ongoing clinical trial in patients with established scars and the planned follow up study will both be conducted at the Fiona Stanley Hospital in Perth with financial support from the company.
お知らせ • Dec 14Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive DirectorPharmaxis Ltd. announced the appointment of experienced senior global pharma executive Dr Simon Green to the Board as an independent nonexecutive director. Dr Green has 30 years of experience in the biotechnology industry focused on the discovery, development and commercialization of life saving medicines. He worked in the USA at leading biotechnology companies Genentech Inc. and Chiron Corporation prior to joining CSL in 1998. Dr Green was actively involved in CSL's global expansion over a 17 year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Dr Green's breadth of skills covers R&D drug development, corporate due diligence, mergers and acquisitions, strategic planning, portfolio management, financial management, intellectual property management, business development, contract management and organizational design. Dr Green was educated at Monash University (Bachelor's Degree with Honours) and the University of Melbourne (Doctor of Philosophy, Biochemistry and Immunology). He is a graduate of the Australian Institute of Company Directors Company Directors Course. Dr Green is a nonexecutive director of Clover Corporation Limited and is the founder and CEO of Immunosis Pty Ltd, a startup diagnostics Company. He is also a Venture Partner and investment advisor at BioScience Managers, a healthcare investment firm and serves on the scientific advisory board for Imunexus Pty Ltd. Dr Green is based in Melbourne Australia and will take up his role as nonexecutive director on 16 December 2022.
お知らせ • Nov 30+ 2 more updatesPharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023Pharmaxis Ltd announced that they will report Q3, 2023 results on Apr 28, 2023
お知らせ • Oct 25Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022, at 10:00 AUS Eastern Standard Time.
お知らせ • Oct 19Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis TrialPharmaxis Ltd. has concluded an interim analysis of data from 6 patients who have completed 6 months' treatment with PXS-5505 in its open label phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis. The phase 2 trial known as MF-101 was cleared by the FDA under the Investigational New Drug (IND) scheme and aims to demonstrate that PXS-5505, the lead asset in Pharmaxis' drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs. These patients have very limited treatment options and a life expectancy of approximately 1 year. A total of 15 patients have been enrolled in the cohort expansion phase of the study with 6 patients having completed 24 weeks of treatment. Four patients have dropped out of the study due to a lack of clinical response. PXS-5505 has been well tolerated with no serious treatment related adverse events reported. 2/6 patients had clinically important improvement in symptoms. 5/6 patients had either stable or improved bone marrow fibrosis scores of 1 grade. 5/6 have stable or improved platelet and/or haemoglobin scores. No reductions were seen in spleen volume. A total of 18 clinical trial sites are now actively recruiting in Australia, South Korea, Taiwan and the US with two more sites due to open in Q4. Recruitment is expected to complete by the end of 2022 with top line results available in Third Quarter 2023. While Pharmaxis' primary focus is the development of PXS-5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancer where it aims to break down the fibrotic tissue in tumours and enhance the chemotherapy treatment. An investigator led phase 1c study in newly diagnosed hepatocellular cancer patients, where PXS-5505 will be used in addition to immunotherapy standard of care, is due to commence recruitment at Rochester University New York in Fourth Quarter 2022.
お知らせ • Sep 26Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring StudyClinical stage drug developer Pharmaxis announced interim data from the clinical trial of its topical anti scarring drug PXS6302 being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM, Director of the Western Australia Burns Service. The trial, known as SOLARIA2, is in 50 adult patients treated daily for scars of greater than one year in age and over 10cm2 in size for a period of 3 months. The first 8 patients treated were on active drug whereas the following 42 are being randomised 1:1 to active or placebo. Preliminary results from open label phase with 8 patients treated for up to 3 months on active drug are: Skin punch biopsies taken 24 hrs after application at the end of the treatment period, show skin penetration and high inhibition of the lysyl oxidase enzymes that, based on preclinical models, are fundamental to the scarring process. Reduction in the scarring biomarkers hydroxyproline and LOX was observed in the biopsies and based on preclinical models of the scarring process, suggests a normalisation of physiological processes and a disease modifying effect. Four patients withdrew from the study after experiencing redness and itching at the site of application that resolved on treatment cessation. In the second placebo controlled phase of the study, 24 out of the planned 42 patients have been recruited. In response to the adverse skin reaction seen with some patients in the unblinded active phase, the treatment regimen has been reduced from once daily to three times a week application to reduce drug exposure whilst maintaining a high level of enzyme inhibition. Final results are expected in H1 2023 when Pharmaxis hopes to confirm an acceptable safety profile, improvements in scar appearance and function for patients on active drug relative to those treated with placebo, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level. In a separate development, UWA researchers last week published the preclinical studies performed in collaboration with Pharmaxis on topical treatment of skin scars with a pan LOX inhibitor that underpinned SOLARIA2. The preclinical studies, published in Nature Communications, clearly demonstrated that lysyl oxidase enzymes play a critical role in scar formation and maintenance by stabilising collagen, and driving scar stiffness and appearance. The inhibition of these enzymes by Pharmaxis' topically applied drug was shown to normalise collagen assembly and reduce fibrosis in different skin scar models (scleroderma, burn and hypertrophic scars). The preclinical data included in the publication were favourably reviewed by the FDA in preIND discussions with Pharmaxis where feedback was also useful in understanding potential endpoints of value in any regulatory process and the limitations of existing patient reported outcome measures. PXS6302 was discovered by the Pharmaxis research team at the company's Frenchs Forest laboratories. The project was supported by a National Health and Medical Research Council (NHMRC) development grant which funded extensive preclinical work executed in collaboration with UWA. The ongoing clinical trial in patients with established scars and the planned follow up study will both be conducted at the Fiona Stanley Hospital in Perth with financial support from Pharmaxis.